Abivax Announces Full Year 2024 Financial Results
Abivax SA - American Depositary Shares (ABVX)
Company Research
Source: GlobeNewswire
Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company’s Board of Directors on March 20, 2025, have been audited by the Company’s statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities, respectively, on March 24, 2025. Marc de Garidel, CEO of Abiv
Show less
Read more
Impact Snapshot
Event Time:
ABVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABVX alerts
High impacting Abivax SA - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ABVX
News
- Abivax (NASDAQ:ABVX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABVX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
- Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
- Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.MarketBeat
- Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.MarketBeat